Lundbeck’s STARSHINE Fades As Idalopirdine Fails First Phase III Alzheimer’s Test
Lundbeck’s 5-HT6 antagonist idalopirdine failed its first Phase III test, but as Axovant awaits data from its Phase III study for a competing Alzheimer’s therapy, it’s still unclear whether the entire drug class is doomed to the same fate.
You may also be interested in...
Lundbeck says it remains committed to developing new Alzheimer's disease drugs with a variety of different mechanisms, after the unsurprising failure of 5HT6 antagonist idalopirdine in two more Phase III studies.
The rebounding Danish CNS specialist raised its 2016 revenue and profit forecasts as it continued to benefit from an ongoing structuring and buoyant sales in the US market, notably for its drugs Brintellix and Rexulti.
Gold standard outcome for Alzheimer's trials may have its difficulties, especially with rater error, but experts say there's no proven alternative to ADAS-cog.